APL Healthcare’s Unit-IV classified as VAI by the USFDA
This inspection is now closed
This inspection is now closed
The protections extend through at least 2035, with the potential for further extensions
The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR
The Japan Patent Office is considered one of the world's most rigorous and meticulous in its review process
The initiative will focus on creating healthier early-life environments, promoting physical activity, identifying risks early, and strengthening preparedness within primary health care systems
Marks significant milestone for breakthrough biologic to treat rare blood cancers
The NeuroSakhi initiative aims to close these gaps by strengthening awareness, building patient support networks and improving engagement between healthcare professionals, patients and caregivers across Punjab
The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets
Subscribe To Our Newsletter & Stay Updated